Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

This summary provides key updates in the healthcare sector, including Kezar Life Sciences halting a lupus treatment trial, challenges in sickle cell gene therapy, Glenview Capital's improvements at ...

FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated ...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc ...

America First Legal examines whether the Biden-Harris White House knew "scant evidence" supports "gender-affirming care" when ...

Welcome to Higher Ground, the faith-centric newsletter focused on the intersection of culture and politics from experienced journalists at The Washington Times.

Two naturally occurring molecules could be the key to sustained weight management, offering an organic alternative to ...

Astria Therapeutics won Food and Drug Administration orphan-drug designation for navenibart, its lead program candidate, for the treatment of the rare genetic disease hereditary angioedema.

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for ...

The Phase 1b/2 open label study of CLD-101 will evaluate the safety and feasibility of administering multiple doses of CLD-101 in patients with newly diagnosed high-grade glioma. Eligible patients, ...